Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Change in Account Payables: 2017-2025

Historic Change in Account Payables for Puma Biotechnology (PBYI) over the last 9 years, with Sep 2025 value amounting to $962,000.

  • Puma Biotechnology's Change in Account Payables rose 116.06% to $962,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year decrease of 145.87%. This contributed to the annual value of -$1.4 million for FY2024, which is 407.35% down from last year.
  • Per Puma Biotechnology's latest filing, its Change in Account Payables stood at $962,000 for Q3 2025, which was up 259.80% from -$602,000 recorded in Q2 2025.
  • Puma Biotechnology's Change in Account Payables' 5-year high stood at $8.9 million during Q3 2021, with a 5-year trough of -$8.9 million in Q4 2021.
  • Over the past 3 years, Puma Biotechnology's median Change in Account Payables value was $517,000 (recorded in 2025), while the average stood at -$4,909.
  • Over the last 5 years, Puma Biotechnology's Change in Account Payables had its largest YoY gain of 1,067.02% in 2021, and its largest YoY loss of 1,863.05% in 2021.
  • Over the past 5 years, Puma Biotechnology's Change in Account Payables (Quarterly) stood at -$8.9 million in 2021, then grew by 4.35% to -$8.5 million in 2022, then soared by 121.54% to $1.8 million in 2023, then tumbled by 209.41% to -$2.0 million in 2024, then spiked by 116.06% to $962,000 in 2025.
  • Its last three reported values are $962,000 in Q3 2025, -$602,000 for Q2 2025, and $517,000 during Q1 2025.